SF 56: Relating to the right to try Act

What it does

This bill relates to Code chapter 144E, the right to try Act. Under current law, an “eligible patient” under the Code chapter is, in part, a person who has a terminal illness. Under the bill, an “eligible patient” also includes, in part, a person who has a life-threatening or severely debilitating illness. Under current law, the Code chapter applies to an “investigational drug, biological product, or device”, meaning a drug, biological product, or device that has successfully completed phase I of a United States food and drug administration (FDA)-approved clinical trial but has not yet been approved for general use by the FDA and that remains under investigation in an FDA-approved clinical trial.

Senate subcommittee · named January 22, 2025

• Sen. Kevin Alons (R) · kevin.alons@legis.iowa.gov
• Sen. Claire Celsi (D)
• Sen. Mike Klimesh (R) · mike.klimesh@legis.iowa.gov

Lobbying · 4 for, 0 against

For: Americans For Prosperity; Goldwater Institute; Iowa Faith and Freedom Coalition; VALOR Iowa

In plain words

1. January 16, 2025Filed in the Senate and sent to the Health and Human Services committee
2. January 21, 2025Senate subcommittee named: Rowley, Campbell and Celsi
3. January 22, 2025Senate subcommittee named: Alons, Celsi and Klimesh
4. January 27, 2025Subcommittee recommended passing it
5. February 10, 2025Approved by the Senate committee, and given a new number: SF 233